UnitedHealth Group has shown unparalleled resiliency, growing adjusted earnings by over 10% despite facing significant headwinds, making it a 'Buy' at historical lows. The company endured a tough period with regulatory scrutiny, higher utilization rates, a cyberattack, and the tragic shooting of a key executive. Q4 marked a bottom for growth and profitability, with revenues of $101 billion and adjusted EPS of $6.74, showing mixed segment profitability.
UnitedHealth Group has removed most mentions of its diversity, equity and inclusion (DEI) policies from its website, TechCrunch reported on Wednesday.
UnitedHealth Group has scrubbed much of its website mentioning its diversity, equity, and inclusion (DEI) policies, including pulling down blog posts and removing large sections from its website, TechCrunch has learned.
The latest trading day saw UnitedHealth Group (UNH) settling at $516.85, representing a +1.09% change from its previous close.
UNH and EPN join forces to enhance pharmacy reimbursement, ensuring fair payments and better stability for independent pharmacies.
UNH CLIMBS HIGHER ON DOWN DAY FOR BROAD MARKET
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
UNH is making significant investments in AI and digital tools to enhance consumer experiences and streamline healthcare processes.
UnitedHealth Group's pharmacy benefit manager, Optum Rx, will eliminate up to 25% of the annual reauthorization requirements for certain drugs, lowering the need of prior authorizations required before patients can access the drugs, the company said on Wednesday.
In the latest trading session, UnitedHealth Group (UNH) closed at $503.80, marking a +0.96% move from the previous day.
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.